Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
2011

Study of Dimebon's Effects on Alzheimer's Disease

publication 10 minutes Evidence: moderate

Author Information

Author(s): Wang Jun, Ferruzzi Mario, Varghese Merina, Qian Xianjuan, Cheng Alice, Xie Mathew, Zhao Wei, Ho Lap, Pasinetti Giulio M

Primary Institution: Mount Sinai School of Medicine

Hypothesis

Can Dimebon modulate β-amyloid-mediated responses in Alzheimer's disease?

Conclusion

Dimebon may improve cognitive function in Alzheimer's disease models without affecting amyloid levels.

Supporting Evidence

  • Dimebon was bioavailable in the brains of mice after oral administration.
  • AD mice treated with Dimebon showed improved spatial memory function.
  • Dimebon treatment did not change levels of total Aβ or soluble oligomeric Aβ in the brain.

Takeaway

Dimebon might help people think better even if it doesn't change the bad stuff in their brains that causes Alzheimer's.

Methodology

Mice were treated with Dimebon and tested for cognitive function using the Morris water maze.

Potential Biases

Potential bias in interpreting the effects of Dimebon due to the lack of significant findings in some measures.

Limitations

The study was conducted in mice, and results may not directly translate to humans.

Participant Demographics

TgCRND8 AD transgenic mice and wild type mice.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1750-1326-6-7

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication